6-K
HUTCHMED (China) Ltd (HCM)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the Month of May 2026
Commission File Number: 001-37710
HUTCHMED (CHINA) LIMITED
(Translation of registrant’s name into English)
48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ⌧ Form 40-F ◻
HUTCHMED (CHINA) LIMITED
Form 6-K
EXHIBIT INDEX
| Exhibit No. | | Description |
|---|---|---|
| | | |
| Exhibit 99.1 | | Announcement relating to the poll results of Annual General Meeting held on May 12, 2026<br><br> |
| | | |
| | | |
| | | |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | HUTCHMED (CHINA) LIMITED | |
|---|---|---|
| | | |
| | | |
| | By: | /s/ Johnny Cheng |
| | Name: | Johnny Cheng |
| | Title: | Chief Financial Officer |
Date: May 12, 2026 3
Exhibit 99.1
Annual General Meeting held on May 1 2 , 202 6 – Poll Results
Hong Kong, Shanghai, & Florham Park, NJ: Tuesday , May 12 , 202 6 : HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX:13) today announces that all ordinary resolutions and special resolution put to its Annual General Meeting (“AGM”) held on May 12, 2026 were duly passed. The poll results of the resolutions were as follows:
| <br><br><br><br>Ordinary Resolutions | Number of Votes (%)* | <br><br>Passed by Shareholders | ||||
|---|---|---|---|---|---|---|
| <br><br>For<br><br> | <br><br>Against<br><br> | <br><br>Withheld^#^ | ||||
| 1. | To consider and adopt the audited Financial Statements, and the Directors’ Report and the Independent Auditors’ Report for the year ended December 31, 2025.<br><br> | 440,149,560<br><br>(99.9998%) | 1,020<br><br>(0.0002%) | 36,866<br><br> | Yes | |
| 2(A). | To re-elect Dr Dan ELDAR as a Director.<br><br><br><br> | 409,558,086<br><br>(93.0477%) | 30,601,245<br><br>(6.9523%) | 26,615 | Yes | |
| 2(B). | To re-elect Dr Weiguo SU as a Director.<br><br><br><br> | 413,398,701<br><br>(93.9185%) | 26,768,655<br><br>(6.0815%) | 18,590 | Yes | |
| 2(C). | To re-elect Mr CHENG Chig Fung, Johnny as a Director.<br><br> | 410,525,379<br><br>(93.2657%)<br><br> | 29,642,001<br><br>(6.7343%) | 18,566 | Yes | |
| 2(D). | To re-elect Ms Edith SHIH as a Director.<br><br><br><br> | 426,101,060<br><br>(96.8043%) | 14,066,301<br><br>(3.1957%) | 18,585 | Yes | |
| 2(E). | To re-elect Ms Ling YANG as a Director.<br><br><br><br> | 428,114,519<br><br>(97.2618%) | 12,052,842<br><br>(2.7382%) | 18,585 | Yes | |
| 2(F). | To re-elect Dr Renu BHATIA as a Director. | 436,786,545<br><br>(99.2319%)<br><br> | 3,380,786<br><br>(0.7681%) | 18,615 | Yes | |
| 2(G). | To re-elect Dr Chaohong HU as a Director.<br><br><br><br> | 440,122,580<br><br>(99.9898%) | 44,806<br><br>(0.0102%) | 18,560 | Yes | |
| 2(H). | To re-elect Professor TAN Shao Weng, Daniel as a Director.<br><br><br><br> | 440,141,241<br><br>(99.9941%) | 26,130<br><br>(0.0059%) | 18,575 | Yes | |
| 2(I). | To re-elect Mr WONG Tak Wai as a Director.<br><br> | 440,128,120<br><br>(99.9911%)<br><br> | 39,265<br><br>(0.0089%) | 18,561 | Yes | |
| 3. | To re-appoint PricewaterhouseCoopers and PricewaterhouseCoopers Zhong Tian LLP as Independent Auditors for Hong Kong financial reporting and US financial reporting purposes, respectively, and to authorize the Directors to fix the Auditors’ remuneration.<br><br> | 394,937,813<br><br>(89.7296%) | 45,204,596<br><br>(10.2704%) | 43,537 | Yes | |
| Special Resolution | ||||||
| 4.<br><br><br><br> | To grant a general mandate to the Directors to issue additional shares of the Company.^<br><br> | 440,097,496<br><br>(99.9851%) | 65,548<br><br>(0.0149%) | 22,902 | Yes | |
| Ordinary Resolution s | ||||||
| 5. | To grant a general mandate to the Directors to repurchase shares of the Company.^<br><br> | 440,120,461<br><br>(99.9933%) | 29,603<br><br>(0.0067%) | 35,382 | Yes | |
| 6. | To approve the adoption of 2026 Share Option Scheme of the Company.^ | 396,856,980<br><br>(90.1613%) | 43,306,320<br><br>(9.8387%) | 22,146 | Yes |
* Percentages rounded to 4 decimal places .
^#^ A vote withheld is not a vote in law and is not counted in the calculation of the proportion of the votes for or against a resolution.
^ The full text of Resolutions 4 , 5 and 6 are set out in the notice of AGM dated April 10 , 202 6 .
Notes:
| (1) | Except for Ms Ling YANG and Professor MOK Shu Kam, Tony who had prior overseas work commitments and were unable to attend the AGM, all Directors of the Company, namely Dr Dan ELDAR, Dr Weiguo SU, Mr CHENG Chig Fung, Johnny, Ms Edith SHIH, Dr Renu BHATIA, Dr Chaohong HU, Professor TAN Shao Weng, Daniel and Mr WONG Tak Wai, attended the AGM, either in person or by means of electronic facilities. |
|---|
| (2) | Number of shares entitling the holders to attend and vote on the resolution at the AGM: 872,335,120 shares, being the total number of issued shares of the Company. The Company did not hold any treasury shares (including any treasury shares held or deposited with Central Clearing and Settlement System) as at the AGM date. |
|---|
| (3) | Number of shares entitling the holders to attend and abstain from voting in favor as set out in Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) at the AGM: Nil. |
|---|
| (4) | Number of shares for holders required under the Listing Rules to abstain from voting at the AGM: Nil. |
|---|
| (5) | The scrutineer for the poll at the AGM was Computershare Investor Services (Jersey) Limited, the Principal Share Registrar of the Company. |
|---|
About HUTCHMED
HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. Іt is committed to the discovery, global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, and the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.
CONTACTS
| Investor Enquiries | +852 2121 8200 / ir@hutch-med.com |
|---|---|
| | |
| Media Enquiries | |
| FTI Consulting – | +44 20 3727 1030 / HUTCHMED@fticonsulting.com |
| Ben Atwell / Tim Stamper | +44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile) |
| Brunswick – Zhou Yi | +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com |
| | |
| Panmure Liberum | Nominated Advisor and Joint Broker |
| Atholl Tweedie / Emma Earl / Rupert Dearden | +44 20 7886 2500 |
| | |
| Cavendish | Joint Broker |
| Geoff Nash / Nigel Birks | +44 20 7220 0500 |
| | |
| Deutsche Numis | Joint Broker |
| Freddie Barnfield / Jeffrey Wong / Duncan Monteith | +44 20 7260 1000 |